FSD Pharma Inc. (HUGE) News

FSD Pharma Inc. (HUGE): $0.88

0.00 (-0.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter HUGE News Items

HUGE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HUGE News Highlights

  • HUGE's 30 day story count now stands at 3.
  • Over the past 18 days, the trend for HUGE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • NOV are the most mentioned tickers in articles about HUGE.

Latest HUGE News From Around the Web

Below are the latest news stories about FSD PHARMA INC that investors may wish to consider to help them evaluate HUGE as an investment opportunity.

FSD Pharma Announces Changes to the Board of Directors

TORONTO, November 28, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is pleased to announce the appointments of Dr. Lakshmi P. Kotra and Mr. Joseph L. Romano to its Board of Directors, effective November 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the Board o

Yahoo | November 28, 2022

InvestmentPitch Media Video Discusses FSD Pharma’s Announcement that the Claim for US$30.2 Million Brought by Dr. Raza Bokhari, the Company’s Former CEO, has been Dismissed in its Entirety

VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, reported that the claim for US$30.2 million brought by Dr. Raza Bokhari, the company’s former CEO, has been dismissed. Dr. Bokhari’s claim that he had been wrongfully dismissed has been dismissed it in its entirety by the arbitra

Yahoo | November 15, 2022

FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari

TORONTO, November 10, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that the claim for USD $30.2 million brought by the Company’s former CEO, Dr. Raza Bokhari, was dismissed yesterday, November 9, 2022. Dr. Bokhari had claimed that he had been wrongfully dismissed. The arbitrator h

Yahoo | November 10, 2022

FSD Pharma receives Nasdaq minimum bid price deficiency notification

FSD Pharma (HUGE) received Nasdaq notification stating the company is not in compliance with the minimum bid price requirement. The company’s class B subordinate voting shares…

Seeking Alpha | September 29, 2022

FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

TORONTO — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that on September 27, 2022 it received a written notification (the “Notification Letter”) from the Nasdaq Stock […]

Financial Post | September 29, 2022

FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available

TORONTO — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it is presenting and participating via the on-demand session at the H.C. Wainwright 24th Annual Global […]

Financial Post | September 12, 2022

FSD Pharma gets clearance to start phase 2 trial of FSD201 in US, Canada

FSD Pharma (HUGE) received clearance from the U.S. Food and Drug Administration ((FDA)) and Health Canada to start a phase 2 trial of FSD201 to treat nociplastic pain associated…

Seeking Alpha | September 6, 2022

FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome

TORONTO, September 06, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it received "Study May Proceed" letter for the Investigational New Drug ("IND") application from the U.S. Food and Drug Administration ("FDA") and "Notice of Authorization" from Health Canada for its Phase 2

Yahoo | September 6, 2022

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium

TORONTO — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that is wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA). The new […]

Financial Post | July 13, 2022

FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates

TORONTO — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the results of its annual general meeting of shareholders (“AGM”), held online and in virtual-only format on June 23, 2022. There were […]

Financial Post | June 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5435 seconds.